Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Vestergaard

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 29, 2023
Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticariaKatrine Baumann, Astrid-Helene Ravn Jørgensen, Jennifer Astrup Sørensen, et al.
Acta Dermato-Venereologica|June 25, 2025
Prevalence of Asthma and Asthma Severity Among Patients with Moderate-Severe Atopic Dermatitis Treated with Advanced SystemicsMaria O Christensen, Ida Vittrup, Jesper Elberling, et al.
Allergy|October 23, 2024
Increasing prevalence of galactose-α-1,3-galactose sensitization in the Danish general adult populationKatja Biering Leth-Møller, Marianne van Hage, Danijela Apostolovic, et al.
American Journal of Clinical Dermatology|April 24, 2025
Correction to: Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysisAmalie Thorsti Møller Rønnstad, Christopher G Bunick, Raj Chovatiya, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 12, 2025
Early response patterns on omalizumab predict long-term outcomes in chronic spontaneous urticariaDitte Georgina Zhang, Mia-Louise Nielsen, Jennifer Astrup Sørensen, et al.
American Journal of Clinical Dermatology|March 5, 2025
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysisAmalie Thorsti Møller Rønnstad, Christopher G Bunick, Raj Chovatiya, et al.
Allergy|September 24, 2025
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future DirectionsMarjolein S de Bruin-Weller, Celeste M Boesjes, Roselie A Achten, et al.
American Journal of Clinical Dermatology|May 5, 2026
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
American Journal of Clinical Dermatology|November 26, 2025
Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
The British Journal of Dermatology|June 27, 2025
Atopic dermatitis epidemiological research methodology: a global scoping reviewChih-Ya Chang, Kaitlyn Chan, Hsuan-Chi Chen, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 29, 2023
Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticariaKatrine Baumann, Astrid-Helene Ravn Jørgensen, Jennifer Astrup Sørensen, et al.
Acta Dermato-Venereologica|June 25, 2025
Prevalence of Asthma and Asthma Severity Among Patients with Moderate-Severe Atopic Dermatitis Treated with Advanced SystemicsMaria O Christensen, Ida Vittrup, Jesper Elberling, et al.
Allergy|October 23, 2024
Increasing prevalence of galactose-α-1,3-galactose sensitization in the Danish general adult populationKatja Biering Leth-Møller, Marianne van Hage, Danijela Apostolovic, et al.
American Journal of Clinical Dermatology|April 24, 2025
Correction to: Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysisAmalie Thorsti Møller Rønnstad, Christopher G Bunick, Raj Chovatiya, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 12, 2025
Early response patterns on omalizumab predict long-term outcomes in chronic spontaneous urticariaDitte Georgina Zhang, Mia-Louise Nielsen, Jennifer Astrup Sørensen, et al.
American Journal of Clinical Dermatology|March 5, 2025
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysisAmalie Thorsti Møller Rønnstad, Christopher G Bunick, Raj Chovatiya, et al.
Allergy|September 24, 2025
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future DirectionsMarjolein S de Bruin-Weller, Celeste M Boesjes, Roselie A Achten, et al.
American Journal of Clinical Dermatology|May 5, 2026
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
American Journal of Clinical Dermatology|November 26, 2025
Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
The British Journal of Dermatology|June 27, 2025
Atopic dermatitis epidemiological research methodology: a global scoping reviewChih-Ya Chang, Kaitlyn Chan, Hsuan-Chi Chen, et al.
Pageof 16